BACKGROUND: A large-scale evaluation of mother-to-child transmission (MTCT) with dolutegravir (DTG)-based antiretroviral treatment (ART) has not been conducted previously. SETTING: Botswana was the first African country to change from efavirenz (EFV)/tenofovir (TDF)/emtricitabine (FTC) to DTG/TDF/FTC first-line ART. METHODS: From April 2015 to July 2018, the Early Infant Treatment Study offered HIV DNA testing at <96 hours of life. Maternal ART regimen was available for screened infants who could be linked to the separate Tsepamo surveillance study database. We evaluated characteristics of HIV-positive infants, and compared MTCT rates by ART regimen for linked infants. RESULTS: Of 10,622 HIV-exposed infants screened, 42 (0.40%) were HIV-positive. In total, 5064 screened infants could be linked to the surveillance database, including 1235 (24.4%) exposed to DTG/TDF/FTC and 2411 (47.6%) exposed to EFV/TDF/FTC. MTCT was rare when either regimen was started before conception: 0/213 [0.00%, 95% confidence interval (CI): 0.00% to 1.72%] on DTG, 1/1497 (0.07%, 95% CI: 0.00% to 0.37%) on EFV. MTCT was similar for women starting each ART regimen in pregnancy: 8/999 (0.80%, 95% CI: 0.35% to 1.57%) for DTG and 8/883 (0.91%, 95% CI: 0.39% to 1.78%) for EFV (risk difference 0.11%, 95% CI: -0.79% to 1.06%). Most MTCT events (4/8 with DTG, 6/9 with EFV) occurred when ART was started <90 days before delivery. Infants exposed to DTG in utero had lower baseline HIV RNA compared with other HIV-infected infants. CONCLUSION: In utero MTCT in Botswana remains rare in the DTG era. No significant MTCT differences were observed between DTG/TDF/FTC and EFV/TDF/FTC. Risk was highest for both groups when ART was started in the third trimester.
BACKGROUND: A large-scale evaluation of mother-to-child transmission (MTCT) with dolutegravir (DTG)-based antiretroviral treatment (ART) has not been conducted previously. SETTING: Botswana was the first African country to change from efavirenz (EFV)/tenofovir (TDF)/emtricitabine (FTC) to DTG/TDF/FTC first-line ART. METHODS: From April 2015 to July 2018, the Early Infant Treatment Study offered HIV DNA testing at <96 hours of life. Maternal ART regimen was available for screened infants who could be linked to the separate Tsepamo surveillance study database. We evaluated characteristics of HIV-positive infants, and compared MTCT rates by ART regimen for linked infants. RESULTS: Of 10,622 HIV-exposed infants screened, 42 (0.40%) were HIV-positive. In total, 5064 screened infants could be linked to the surveillance database, including 1235 (24.4%) exposed to DTG/TDF/FTC and 2411 (47.6%) exposed to EFV/TDF/FTC. MTCT was rare when either regimen was started before conception: 0/213 [0.00%, 95% confidence interval (CI): 0.00% to 1.72%] on DTG, 1/1497 (0.07%, 95% CI: 0.00% to 0.37%) on EFV. MTCT was similar for women starting each ART regimen in pregnancy: 8/999 (0.80%, 95% CI: 0.35% to 1.57%) for DTG and 8/883 (0.91%, 95% CI: 0.39% to 1.78%) for EFV (risk difference 0.11%, 95% CI: -0.79% to 1.06%). Most MTCT events (4/8 with DTG, 6/9 with EFV) occurred when ART was started <90 days before delivery. Infants exposed to DTG in utero had lower baseline HIV RNA compared with other HIV-infected infants. CONCLUSION: In utero MTCT in Botswana remains rare in the DTG era. No significant MTCT differences were observed between DTG/TDF/FTC and EFV/TDF/FTC. Risk was highest for both groups when ART was started in the third trimester.
Authors: Risa M Hoffman; Vivian Black; Karl Technau; Karin Joan van der Merwe; Judith Currier; Ashraf Coovadia; Matthew Chersich Journal: J Acquir Immune Defic Syndr Date: 2010-05-01 Impact factor: 3.731
Authors: Alexander C Ewing; Sascha R Ellington; Jeffrey B Wiener; Charles S Chasela; Gerald Tegha; Julie A E Nelson; Denise J Jamieson; Charles van der Horst; Athena P Kourtis Journal: Pediatr Infect Dis J Date: 2019-05 Impact factor: 2.129
Authors: Robert D Stewart; C Edward Wells; Scott W Roberts; Vanessa L Rogers; Barbara S McElwee; Donald D McIntire; Jeanne S Sheffield Journal: Am J Obstet Gynecol Date: 2014-04-15 Impact factor: 8.661
Authors: Rebecca Zash; Lewis Holmes; Modiegi Diseko; Denise L Jacobson; Sean Brummel; Gloria Mayondi; Arielle Isaacson; Sonya Davey; Judith Mabuta; Mompati Mmalane; Tendani Gaolathe; M Essex; Shahin Lockman; Joseph Makhema; Roger L Shapiro Journal: N Engl J Med Date: 2019-07-22 Impact factor: 91.245
Authors: Maryanne Ibrahim; Kenneth Maswabi; Gbolahan Ajibola; Sikhulile Moyo; Michael D Hughes; Oganne Batlang; Maureen Sakoi; Chloe Auletta-Young; Laura Vaughan; Shahin Lockman; Patrick Jean-Philippe; Xu Yu; Matthias Lichterfeld; Daniel R Kuritzkes; Joseph Makhema; Roger L Shapiro Journal: J Int AIDS Soc Date: 2018-05 Impact factor: 6.707
Authors: Megan Landes; Monique van Lettow; Ernest Nkhoma; Beth Tippett Barr; Zinenani Truwah; Erik Shouten; Andreas Jahn; Andrew Auld; Thokozani Kalua; Joep J van Oosterhout Journal: J Int AIDS Soc Date: 2019-06 Impact factor: 5.396
Authors: Steve Kanters; Marco Vitoria; Meg Doherty; Maria Eugenia Socias; Nathan Ford; Jamie I Forrest; Evan Popoff; Nick Bansback; Sabin Nsanzimana; Kristian Thorlund; Edward J Mills Journal: Lancet HIV Date: 2016-09-06 Impact factor: 12.767
Authors: Alyson S Smith; Soneela Ankam; Chen Farhy; Lorenzo Fiengo; Ranor C B Basa; Kara L Gordon; Charles T Martin; Alexey V Terskikh; Kelly L Jordan-Sciutto; Jeffrey H Price; Patrick M McDonough Journal: J Pharmacol Toxicol Methods Date: 2022-02-08 Impact factor: 2.285
Authors: Lynn Sodai Zijenah; Tsitsi Bandason; Wilbert Bara; Maria Mary Chipiti; David Allan Katzenstein Journal: AIDS Patient Care STDS Date: 2022-04 Impact factor: 5.078